Molecular markers and changes of computed tomography appearance in lung adenocarcinoma with ground-glass opacity

Japanese Journal of Clinical Oncology

Volumn 37, Issue 12, 2007, Pages 907-912

  Yoshida, Yukihiro ^a   Kokubu, Akiko ^a   Suzuki, Kenji ^a   Kuribayashi, Hidehiko ^a   Tsuta, Koji ^a   Matsuno, Yoshihiro ^a   Kusumoto, Masahiko ^a   Kanai, Yae ^b   Asamura, Hisao ^a   Hirohashi, Setsuo ^a,b   Shibata, Tatsuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Adenocarcinoma; Bronchioloalveolar; Epidermal growth factor; Lung neoplasms; Spiral computed receptor; Tomography; Tumor suppressor protein p53

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; MOLECULAR MARKER; PROTEIN P53;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; FREQUENCY ANALYSIS; GENE INACTIVATION; GENE MUTATION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MALE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; OUTCOME ASSESSMENT; PATTERN RECOGNITION; RADIODIAGNOSIS;

ADENOCARCINOMA; ADULT; AGED; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GENE SILENCING; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TOMOGRAPHY, SPIRAL COMPUTED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 38749151354     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym139     Document Type: Article

References (26)

1. Kaneko M, Eguchi K, Ohmatsu H, Kakinuma R, Naruke T, Suemasu K, et al. Peripheral lung cancer: Screening and detection with low-dose spiral CT versus radiography. Radiology 1996;201:798-802.
2. Nakata M, Sawada S, Saeki H, Takashima S, Mogami H, Teramoto N, et al. Prospective study of thoracoscopic limited resection for ground-glass opacity selected by computed tomography. Ann Thorac Surg 2003;75:1601-5.
3. Kakinuma R, Ohmatsu H, Kaneko M, Kusumoto M, Yoshida J, Nagai K, et al. Progression of focal pure ground-glass opacity detected by low-dose helical computed tomography screening for lung cancer. J Comput Assist Tomogr 2004;28:17-23.
4. Aoki T, Nakata H, Watanabe H, Nakamura K, Kasai T, Hashimoto H, et al. Evolution of peripheral lung adenocarcinomas: CT findings correlated with histology and tumor doubling time. AJR Am J Roentgenol 2000;174:763-8.
5. Kodama K, Higashiyama M, Yokouchi H, Takami K, Kuriyama K, Kusunoki Y, et al. Natural history of pure ground-glass opacity after long-term follow-up of more than 2 years. Ann Thorac Surg 2002;73:386-92.
6. Takashima S, Maruyama Y, Hasegawa M, Yamanda T, Honda T, Kadoya M, et al. CT findings and progression of small peripheral lung neoplasms hwing a replacement growth pattern. AJR Am J Roentgenol 2003; 180:817-26.
7. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
8. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
9. Yatabe Y, Kosaka T, Takahashi T, Mitsudomi T. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Aim J Surg Pathol 2005;29:633-9.
10. Yoshida Y, Shibata T, Kokubu A, Tsuta K, Matsuno Y, Kanai Y, et al. Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung. Lung Cancer 2005;50:1-8.
11. Oshiro Y, Kusumoto M, Matsuno Y, Asamura H, Tsuchiya R, Terasaki H, et al. CT findings of surgically resected large cell neuroendocrine carcinoma of the lung in 38 patients. AJR Am J Roentgenol 2004;182:87-91.
12. Tateishi U, Muller NL, Johkoh T, Maeshima A, Asamura H, Satake M, et al. Mucin-producing adenocarcinoma of the lung: Thin-section computed tomography findings in 48 patients and their effect on prognosis. J Comput Assist Tomogr 2005;29:361-8.
13. Asamura H, Suzuki K, Watanabe S, Matsuno Y, Maeshima A, Tsuchiya R. A clinicopathological study of resected subcentimeter lung cancers: A favorable prognosis for ground glass opacity lesions. Ann Thorac Surg 2003;76: 1016-22.
14. Abramoff MD, Magelhaes PJ, Ram SJ. Image Processing with Image J. Biophotonics International 2004;11:36-43.
15. Schwarts M. A biomathematical approach to clinical tumor growth. Cancer 1961;14:1272-94.
16. Emmert-Buck MR, Bónner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, et al. Laser capture microdissection. Science 1996;274:998-1001.
17. Ebright MI, Zakowski MF, Martin J, Venkatraman ES, Miller VA, Bains MS, et al. Clinical patern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg 2002;74:1640-6.
18. Etoh T, Kanai Y, Ushijima S, Nakagawa T, Nakanishi Y, Sasako M, et al. Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am J Pathol 2004;164:689-99.
19. Terasaki H, Niki T, Matsuno Y, Yamada T, Maeshima A, Asamum H, et al. Lung adenocarcinoma with mixed bronchioloalveolar and invasive companents: Clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. Am J Surg Pathol 2003;27:937-51.
20. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:6829-37.
21. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg 1975;70:606-12.
22. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-7.
23. Lubin R, Zalcman G, Bouchet L, Tredanel J, Legros Y, Cazals D, et al. Serum pp53 antibodies as early markers of lung cancer. Nat Med 1995;1:701-2.
24. Mitsudomi T, Suzuki S, Yatabe Y, Nishio M, Kuwabara M, Gotoh K, et al. Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer. J Natl Cancer Inst 1998;90:1563-8.
25. MacMahon H, Austin JH, Gamsu G, Herold CJ, Jett JR, Naidich DP, et al. Fleischner Society; Guidelines for management of small pulmonary nodules detected on CT scans:a statement from the Fleischner Society. Radiology 2005;237:395-400.
26. Kobayashi T, Tsuda H, Noguchi M, Hirohashi S, Shimosato Y, Goya T, et al. Association of point mutation in c-Ki-ras oncogene in lung adenocarcinoma with particular reference to cytologic subtypes. Cancer 1990;66:289-94.